Introduction: Local skin responses (LSRs) are
INTRODUCTION
Actinic keratosis (AK) is a skin condition caused by excessive, prolonged exposure to ultraviolet Electronic supplementary material The online version of this article (doi:10.1007/s13555-014-0059-9) contains supplementary material, which is available to authorized users.
light [1] . Topical treatments for AK include retinoids [2] , colchicine [3] , and, more commonly, several formulations of 5-fluorouracil, imiquimod, and diclofenac sodium 3% gel [4, 5] . Another approach is the use of ingenol mebutate gel, approved in the USA [6] , European Union [7] , Australia, Brazil, and Canada for the topical treatment of AK in adults.
Each treatment offers specific advantages and disadvantages as well as potential complications. The most common resulting adverse effects (AEs) are local skin responses (LSRs) at the treatment area, categorized clinically as erythema, edema, erosion/ulceration, scabbing/crusting, weeping/ exudates, vesicles/pustules, and flaking/scaling/ dryness.
Historically, LSRs are graded subjectively (0 = none, 1 = mild, 2 = moderate, and 3 = severe) [5] . During the clinical development of ingenol mebutate, the Food and Drug Administration (FDA) indicated that such subjective grading of LSRs was insufficient to quantify responses to a topically applied treatment [8] . It recommended the development of a quantitative tool for the assessment of LSRs, incorporating a photographic scale with numeric grades of severity, each of which should include clinical descriptors defining a particular level of response. The descriptors were to be sufficiently detailed to minimize inter-observer variability.
As a consequence, the LSR grading scale was developed. The scale has since been used in 15 AK studies of ingenol mebutate [9] [10] [11] [12] [13] [14] [15] The scores derived from the scale can be used in two ways. First, the individual LSR category score represents the type and time course of the skin response that a topical agent may cause during and after treatment. Second, the composite (total) numerical score of the individual LSRs for each patient provides a useful tool for analyzing the onset, peak, and resolution of the range of LSRs in treated patients. This composite LSR score represents the sum of the scores graded from 0 to 4 on all six individual LSR categories. 
Compliance with Ethics Guidelines
The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. Figure 2 shows the time course of mean composite LSR scores for face/scalp treatment (n = 547) [12] . LSRs were transient and typically occurred within 1 day of therapy initiation, peaking in intensity up to 1 week following completion of treatment. These effects typically resolved within 2 weeks of therapy. Figure 3 shows representative examples of typical LSR progression by study visit, with resolution to a level lower than baseline by day 57. Erythema and flaking were the most common LSRs, with vesiculation and erosion occurring less commonly. Grade 4 vesiculation/erosion was only seen in 5% of patients. The mean maximum composite LSR score over the entire study duration was 9. with ingenol mebutate 0.015% had their maximum composite LSR score at day 4 ( Fig. 2) . Table 1 shows a summary of composite LSR scores for face/scalp treatment; Fig. 4 shows the distribution of ingenol mebutate-treated patients who fell within each range of maximum composite LSR score (0-24). The majority of patients (81.3%) with face/scalp lesions had maximum composite LSR scores between 1 and 12. Only 1.8% of these patients had composite LSR scores in the most intense range (19) (20) (21) (22) (23) (24) . Most patients (99.3%) in the vehicle group experienced a maximum composite LSR score between 0 and 12. Table 2 shows maximum LSR scores for the face/scalp studies.
RESULTS

Studies of the Face/Scalp
Studies of the Trunk/Extremities
The time course of the mean composite LSR score is shown in Fig. 5 for AK treatment on the trunk/extremities (n = 458, ITT population) [12] . LSRs were transient and typically occurred within 1 day of therapy initiation, peaking in intensity up to 1 week following treatment completion. These effects typically resolved within 4 weeks of therapy initiation [6] . Erythema and flaking were the most common LSRs; vesiculation and erosion occurred less commonly. Grade 4 vesiculation/ erosion was only seen in 1% of patients.
The mean maximum composite LSR score for patients given ingenol mebutate 0.05% was 6.8 (SD, 3.5) compared with 1.6 (SD, 1.5) for patients given vehicle. The maximum composite LSR score was higher than the baseline LSR score in 96.4% of patients receiving ingenol mebutate 0.05% and 31.0% of patients receiving vehicle. The maximum composite LSR score for patients treated with ingenol mebutate 0.05% occurred on day 3 for 55.1%, on day 8 for 32.4%, and on day 15 for Table 1 shows a summary of composite LSR scores for trunk/extremities locations; Fig. 4 shows the distribution of ingenol mebutate- (Fig. 6) .
DISCUSSION
LSRs are a common feature of the numerous ablative and non-ablative approaches to treat AK. These have generally been characterized as In clinical studies of ingenol mebutate in AK, including the four phase III studies discussed here [12] and several phase I and II studies [9, 11, 16, 17] , the scale effectively recorded the onset, maximum severity, and subsequent return to baseline for each one of six treatment-related responses and generated an overall composite score, taking all potential types of LSR into consideration. In the four phase III studies, the scale demonstrated that LSRs associated with ingenol mebutate during treatment for AK were transient, were detectable within 1 day of treatment initiation and peaked in intensity within the first week following completion of treatment. These effects generally resolved within 2 weeks of treatment initiation for areas on the face and scalp and within 4 weeks of treatment initiation for areas on the trunk and extremities; while exhibiting a longer peak than on the face and scalp, LSRs on the trunk and extremities were of a lower intensity [6, 12] . There was good reproducibility between the individual phase III studies. The tabular and graphic representations of LSR data presented here illustrate the ease with which rapid comparison of individual LSRs can be made and translated into a meaningful dialog with candidate patients for topical field therapy.
More recently, the scale has been successfully used to assess LSRs in a first-in-man study of LEO43204 for topical treatment of AK on the forearms [18] and has also been used during treatment with ingenol mebutate for superficial basal cell carcinomas [19, 20] .
Previous AK studies have not uniformly reported objectively the incidence, frequency, 
